Table 2.
Geometric mean hormone concentrations (95% CI) by study and case-control status
| Study | Number1 | Oestradiol, pmol/L |
Calculated free oestradiol, pmol/L |
Oestrone, pmol/L |
Luteal phase progesterone, nmol/L |
Androstenedio ne, nmol/L |
DHEAS, nmol/L |
Testosterone, nmol/L |
Calculated free testosterone, pmol/L |
SHBG, nmol/L | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CLUE I, USA | Cases | 21 | 172 (134–222) | 2.03 (1.55–2.64) | 252 (211–301) | 5.32 (1.73–16.3) | 2.98 (2.31–3.85) | 3903 (2787–5465) | - | - | 69.9 (58.0–84.2) |
| Controls | 42 | 168 (137–206) | 1.85 (1.51–2.26) | 239 (207–275) | 9.62 (5.47–16.9) | 2.88 (2.42–3.43) | 3853 (3023–4910) | - | - | 74.3 (65.3–84.4) | |
| Columbia, USA | Cases | 13 | 239 (165–347) | 3.26 (2.24–4.75) | - | - | - | - | 1.00 (0.79–1.28) | 13.7 (9.86–19.1) | 48.2 (34.3–67.7) |
| Controls | 24 | 316 (257–387) | 4.05 (3.34–4.92) | - | - | - | - | 0.86 (0.73–1.02) | 10.7 (9.10–12.7) | 56.6 (48.3–66.4) | |
| EPIC, Europe | Cases | 206 | 318 (285–355) | 4.60 (4.13–5.12) | 384 (354–416) | 8.42 (6.30–11.3) | 5.59 (5.22–5.98) | 3712 (3469–3972) | 1.70 (1.60–1.81) | 25.2 (23.2–27.3) | 43.5 (40.6–46.6) |
| Controls | 408 | 296 (275–318) | 4.25 (3.94–4.60) | 360 (339–383) | 12.3 (9.84–15.4) | 4.92 (4.68–5.18) | 3341 (3169–3522) | 1.56 (1.49–1.63) | 23.3 (21.8–24.8) | 43.0 (40.9–45.3) | |
| Guernsey, UK | Cases | 32 | 323 (253–412) | 3.16 (2.39–4.17) | - | 10.7 (5.84–19.5) | - | 2253 (1410–3599) | 1.17 (0.97–1.40) | 13.2 (11.3–15.5) | 68.6 (59.5–79.1) |
| Controls | 94 | 282 (246–323) | 3.02 (2.52–3.62) | - | 10.6 (7.25–15.4) | - | 2548 (1924–3375) | 1.12 (1.02–1.23) | 13.4 (11.6–15.5) | 61.5 (55.8–67.7) | |
| Nurses’ Health Study II phase 1, USA | Cases | 139 | 182 (166–199) | 2.30 (2.12–2.49) | 150 (142–159) | 45.7 (41.1–50.8) | 3.91 (3.68–4.16) | 2302 (2129–2489) | 0.92 (0.87–0.99) | 11.3 (10.5–12.2) | 57.9 (53.8–62.3) |
| Controls | 268 | 164 (153–177) | 2.08 (1.95–2.22) | 145 (138–151) | 43.5 (39.9–47.4) | 3.89 (3.72–4.06) | 2208 (2089–2333) | 0.90 (0.86–0.94) | 10.9 (10.3–11.5) | 58.5 (55.5–61.8) | |
| Nurses’ Health Study II phase 2, USA | Cases | 105 | 193 (175–213) | 2.21 (2.02–2.42) | 161 (150–173) | 40.7 (34.6–47.9) | - | 2838 (2556–3151) | 0.91 (0.85–0.98) | 9.6 (8.7–10.5) | 70.6 (65.3–76.3) |
| Controls | 203 | 186 (174–199) | 2.25 (2.11–2.40) | 163 (154–171) | 38.1 (33.9–42.9) | - | 2642 (2449–2851) | 0.91 (0.87–0.96) | 10.6 (10.0–11.3) | 62.4 (59.0–66.0) | |
| NYU WHS phase2, USA | Cases | 137 | - | - | - | - | 4.30 (3.96–4.67) | 3978 (3625–4366) | 1.01 (0.91–1.12) | 14.0 (12.4–15.8) | 48.1 (44.1–52.4) |
| Controls | 258 | - | - | - | - | 4.07 (3.83–4.33) | 3869 (3598–4161) | 0.95 (0.88–1.03) | 13.1 (11.9–14.3) | 47.8 (44.8–51.0) | |
| ORDET, Italy | Cases | 84 | 300 (274–329) | 3.66 (3.34–4.00) | - | 38.2 (32.7–44.6) | 5.26 (4.38–6.32) | 3856 (3153–4715) | 0.85 (0.75–0.97) | 9.9 (8.5–11.6) | 62.0 (56.6–68.0) |
| Controls | 336 | 282 (259–306) | 3.50 (3.23–3.79) | - | 32.4 (28.3–37.1) | 5.79 (5.38–6.23) | 3921 (3604–4265) | 0.84 (0.79–0.90) | 10.1 (9.3–10.8) | 59.8 (57.1–62.6) |
Numbers are for women with known phase of cycle and values for oestradiol (except for NYU WHS where numbers are for women with values for testosterone).
- indicates data not available.
Geometric mean hormone concentrations for Nurses’ Health Study II are obtained using the follicular phase data for oestradiol, calculated free oestradiol and oestrone and using the luteal phase data for all other hormones.
CLUE I = Washington County, MD Study “Give us a clue to cancer and heart disease”; EPIC = European Prospective Investigation into Cancer and Nutrition; NYU WHS = New York University Women’s Health Study; ORDET = Study of Hormones and Diet in the Etiology of Breast Tumors.